One‐year clinical outcome of biodegradable polymer sirolimus‐eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry

Background The ULISSE registry has demonstrated the real‐world performance of the Ultimaster biodegradable polymer sirolimus‐eluting stent (BP‐SES) in a large cohort of patients undergoing percutaneous coronary intervention, including a large proportion of patients presenting with acute myocardial i...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2019-12, Vol.94 (7), p.972-979
Main Authors: Moscarella, Elisabetta, Ielasi, Alfonso, Beneduce, Alessandro, Ferrante, Giuseppe, Pivato, Andrea Carlo, Chiarito, Mauro, Cappelletti, Alberto, Perfetti, Giulia, Magni, Valeria, Prati, Eugenio, Falcone, Stefania, Pierri, Adele, De Martini, Stefano, Montorfano, Matteo, Parisi, Rosario, Rutigliano, David, Locuratolo, Nicola, Anzuini, Angelo, Calabrò, Paolo, Tespili, Maurizio, Margonato, Alberto, Benassi, Alberto, Briguori, Carlo, Fabbiocchi, Franco, Reimers, Bernhard, Bartorelli, Antonio, Colombo, Antonio, Godino, Cosmo
Format: Article
Language:English
Subjects:
Absorbable Implants
acute myocardial infarction
Aged
Biodegradability
biodegradable‐polymer sirolimus‐eluting coronary stent
Biodegradation
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - adverse effects
Clinical outcomes
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - mortality
Coronary Artery Disease - therapy
Coronary Thrombosis - etiology
Dialysis
Drug-Eluting Stents
Electrocardiography
Epidermal growth factor receptors
Female
Heart attacks
Heart rate
Humans
Implantation
Implants
Incidence
Italy
Kidney diseases
Lesions
Male
Middle Aged
Myocardial infarction
Myocardial Infarction - diagnostic imaging
Myocardial Infarction - mortality
Myocardial Infarction - therapy
Percutaneous Coronary Intervention - adverse effects
Percutaneous Coronary Intervention - instrumentation
Percutaneous Coronary Intervention - mortality
percutaneous coronary interventions
Polymers - chemistry
Progression-Free Survival
Prosthesis Design
Rapamycin
Recurrence
Registries
Regression analysis
Retrospective Studies
Risk Factors
Sirolimus - administration & dosage
Sirolimus - adverse effects
stent thrombosis
Stents
Thromboembolism
Thrombosis
Time Factors
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The ULISSE registry has demonstrated the real‐world performance of the Ultimaster biodegradable polymer sirolimus‐eluting stent (BP‐SES) in a large cohort of patients undergoing percutaneous coronary intervention, including a large proportion of patients presenting with acute myocardial infarction (AMI). Methods We performed a subgroup analysis of the ULISSE registry in AMI patients and compared the outcomes of this vulnerable cohort with that of patients presenting without AMI (non‐AMI). The primary end point was the incidence of 1‐year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV‐MI), and clinically indicated target lesion revascularization (TLR). Results Of 1,660 patients included in the ULISSE registry, 381(23%) presented with AMI, 207(54.3%) non‐ST elevation myocardial infarction, and 174(45.7%) ST‐elevation myocardial infarction. Compared with non‐AMI patients, those with AMI were more frequently female and smokers, with lower left ventricular ejection fraction (LVEF) and chronic kidney disease requiring dialysis. At 1 year, TLF rate was significantly higher in AMI than non‐AMI patients (7.9 vs. 4.1%; HR 1.98, CI 95% 1.22–3.23; p = .005) driven by higher rate of cardiac death (4.0 vs. 1.1%; HR 3.59, CI 95% 1.64–7.88; p = .01) and TV‐MI (2.8 vs 0.9%; HR 2.99,CI 95% 1.22–7.37; p = .01), without differences in TLR rate (4.3 vs. 2.9%,HR 0.66, CI95% 0.35–1.25; p = .2). At multivariate Cox regression analysis, eGFR
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.28305